Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma.
Jatin ShahSharon ShachamMichael KauffmanPatrick DanieleDimitrios TomarasGabriel TremblayRene-Olivier CasasnovasMarie MaerevoetJosee ZijlstraGeorge FollowsJoost S P VermaatNagesh KalakondaAndre Henri GoySylvain ChoquetEric Van Den NesteBrian T HillCatherine ThieblemontFederica CavalloFátima de la CruzJohn KuruvillaNada HamadReda BouabdallahUlrich JägerPaolo CaimiRonit GurionKrzysztof WarzochaSameer BakhshiJuan Manuel SanchoMichael SchusterMiklós EgyedFritz OffnerTheodoros P VasilakopoulosPriyanka SamalAgnes NagyMatthew KuMiguel Ángel Canales AlbendeaPublished in: Future oncology (London, England) (2021)
Aim: Evaluate health-related quality of life (HRQoL) and health utility impact of single-agent selinexor in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma. Patients & methods: Functional Assessment of Cancer Therapy (FACT) - Lymphoma and EuroQoL five-dimensions five-levels data collected in the single-arm Phase IIb trial SADAL (NCT02227251) were analyzed with mixed-effects models. Results: Treatment responders maintained higher FACT - Lymphoma (p ≤ 0.05), FACT - General (p < 0.05) and EuroQoL five-dimensions five-levels index scores (p < 0.001) beginning in cycle 3. The estimated difference in health state utilities for treatment response and progressive disease was both statistically significant and clinically meaningful (mean difference: 0.07; p = 0.001). Conclusion: In patients with relapsed/refractory diffuse large B-cell lymphoma, objective response to selinexor was associated with HRQoL maintenance, reduction in disease-related HRQoL decrements and higher health utilities.
Keyphrases
- diffuse large b cell lymphoma
- epstein barr virus
- healthcare
- public health
- mental health
- cancer therapy
- end stage renal disease
- health information
- multiple sclerosis
- health promotion
- chronic kidney disease
- clinical trial
- newly diagnosed
- ejection fraction
- prognostic factors
- drug delivery
- study protocol
- randomized controlled trial
- skeletal muscle
- adipose tissue
- metabolic syndrome
- climate change
- weight loss
- combination therapy
- phase iii
- big data
- open label
- hodgkin lymphoma
- phase ii